Ruxolitinib (INCB018424)

inquiry

Cat No.

CEI-0187

Description

Ruxolitinib (INCB018424) can inhibit JAK1, JAK2 and JAK3 with IC50 of 3 nM, 5 nM and 332 nM.

CAS_No

941678-49-5

Molecular Weight

306.37

Purity

>99%

Storage

2 years at -20centigrade Powder

Targets

Jak1, Jak2, Jak3

Molecular Formula

C17H18N6

Chemical Name

(3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

Solubility

DMSO 61 mg/mL Water

In vitro

Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, and INCB018424 (Ruxolitinib) inhibit Jak1, Jak2, and Jak3 with IC50 of 3 nM, 5 nM and 332 nM, respectively. Ruxolitinib (INCB-018424) is developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs). Ruxolitinib (Jakafi; Incyte) is a small-molecule inhibitor of JAK1/2 that has proved to be effective at reducing splenomegaly and ameliorating symptoms in myeloproliferative neoplasms.

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry